Lineage Cell Therapeutics Inc. (LCTX)
LCTX trades on NYSE in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/876343/000119312526093992/0001193125-26-093992-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | LCTX on NYSE |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0000876343 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | CA |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $14.6M |
| Net income | -$63.5M |
| Operating income | -$36.6M |
| Net margin | -436.5% |
| Operating margin | -251.6% |
| Revenue growth | +53.2% |
| Cash | $40.8M |
| Total assets | $112.6M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 13.8× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-12 |
| Cash and burn | $26.5M cash; operating cash flow -$6.5M a quarter. | Report 2026-09-30 |
| Shares outstanding | 252,954,764 (2026-11-09); 230,327,537 a year earlier; 174,986,671 three years earlier. | Cover page 2026-11-09 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 1 424B5 takedowns | Latest 2026-03-11 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Baker Tilly US, LLP, San Diego, California, United States; changed auditors 1 time in 24 months | 8-K 4.01 2025-06-09 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $24K, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $1.4M | $4.2M | -$5.6M | $26.5M | No debt tags | $10.8M | 10-Q 2026-11-12 |
| Q2 2026 2026-06-30 | $1.1M | $1.5M | -$7.2M | $37.4M | No debt tags | $13.1M | 10-Q 2026-08-06 |
| Q1 2026 2026-03-31 | $1.7M | -$4.8M | -$8.1M | $35.9M | No debt tags | $14.8M | 10-Q 2026-05-12 |
| Q4 2025 2025-12-31 | $6.6M | $851K | -$4.9M | $40.8M | No debt tags | $14.6M | 10-K 2026-03-05 |
| Q3 2025 2025-09-30 | $3.7M | -$29.8M | -$3.6M | $40.5M | No debt tags | $10.8M | 10-Q 2026-11-12 |
| Q2 2025 2025-06-30 | $2.8M | -$30.5M | -$5.5M | $42.3M | No debt tags | $10.9M | 10-Q 2026-08-06 |
| Q1 2025 2025-03-31 | $1.5M | -$4.1M | -$4.9M | $47.9M | No debt tags | $9.6M | 10-Q 2026-05-12 |
| Q4 2024 2024-12-31 | $2.9M | -$3.3M | -$6.3M | $45.8M | No debt tags | $9.5M | 10-K 2026-03-05 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3 | 2026-03-11 |
| Latest annual report | 10-K | 2026-03-05 |
| Latest quarterly / interim | 10-Q | 2026-11-12 |
| Latest current report | 8-K | 2026-11-12 |
| Latest proxy | DEFA14A | 2026-04-29 |
Source: SEC EDGAR submissions feed, 1,004 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -10.8% |
| 1 month | 0.0% |
| 3 months | -14.2% |
| Year to date | -45.5% |
| 1 year | -49.4% |
| From 52-week high | -53.6% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| IKT | Inhibikase Therapeutics Inc. | $1.45 | -4.61% | $203.4M |
| ARTV | Artiva Biotherapeutics Inc. | $3.96 | -1.25% | $195.8M |
| CGEN | Compugen Ltd. | $2.04 | -2.86% | $193.0M |
| PALI | Palisade Bio Inc. | $1.03 | -8.04% | $184.7M |
| CABA | Cabaletta Bio Inc. | $1.11 | -13.28% | $239.4M |
| IVVD | Invivyd Inc. | $0.5377 | -7.63% | $158.5M |
| PLX | Protalix BioTherapeutics Inc. (DE) | $3.03 | -0.66% | $255.5M |
| IPHA | Innate Pharma S.A. ADS | $1.41 | -1.06% | $156.9M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier